MAJOR RECTAL CANCER TREATMENT BREAKTHROUGH
A groundbreaking cancer trial at Sloan Kettering of a new drug, dostarlimab, has shown unprecedented results: the cancer disappeared in 100% of the trial participants.
Although not for this particular program, National Cancer Center has funded post-doctoral cancer research at Memorial Sloan Kettering Cancer Center and we commend the scientists there for this keenly important advance.
National Cancer Center is currently funding a colorectal project at Nebraska University Medical Center.
For more information on our funding click here
To contribute to NCC’s research funding, please donate now
